Tulsa Medical Laboratories is pleased to announce the addition of three new tests to our molecular testing menu; the Aptima Bacterial Vaginosis Assay, the Aptima Mycoplasma Genitalium Assay and the Aptima CV/TV (Candida Vaginitis/Trichomonas Vaginalis).
- The Aptima BV assay is an FDA approved in vitro qualitative NAAT that utilizes real time TMA for detection and quantitation of ribosomal RNA from bacteria associated with bacterial vaginosis, including Lactobacillus (L.gasseri, L.crispatus, and L. jensenii), Gardnerella vaginalis and Atopobium vaginae.
The assay gives a qualitative result for BV and does not report for individual organisms.
- The Aptima Mycoplasma genitalium assay is an FDA approved in vitro qualitative NAAT for the detection of rRNA from Mycoplasma genitalium. The assay is intented as an aid in the diagnosis of M. genitalium urogenital infections in male and female patients suspected of M. genitalium infection.
- The CV/TV assay is an FDA approved, qualitative in vitro NAAT for the detection of RNA from microorganisms associated with vulvovaginal candidiasis and trichomoniasis. The assay uses real time TMA to detect and report results for the following organisms;
- Candida species group (C. albicans, C. tropicalis, C. parapsilosis, C. dublinensis)
- Candida glabrata
- Trichomonas vaginalis
These assays are not available from the thin prep pap test vial and must be collected in the Aptima Multi test swab (orange Aptima tube). These assays will replace the current BD affirm vaginitis panel which will not be available after March 13, 2020. The assays may be ordered individually or as a “full vaginal panel” which would be CT/NG, BV, CV/TV and M. genitalium. We are excited to be able to offer a one-swab solution for vaginitis testing.
If you are interested in ordering supplies for these tests or have questions about the tests please feel free to contact the molecular department supervisor, Julie Gregg at (918) 281-6865.